LXEO · Lexeo Therapeutics, Inc.
$3.15
-0.08 (-2.48%)
At close · Oct 12
Return incl. dividend (before tax)
Market Cap
$265.01M
Shares
82.05M
Volume · Oct 12
33.6K
Avg daily vol (3M)
1.19M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.23
Open$3.21
Day$3.12–3.34
52W close$3.14–10.63
Avg vol 30d1.5M
Short int19.2M · 23.5% float · 9.0d
Short vol44%
Last earningsSep 22, 2026
DataNov 2023–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Jan 27, 2027
Est · unconfirmed
· in 15 wks
filed Aug 12, 2026
call held Sep 22, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$87.30M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-9,252.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+96.5%
Year over year · more shares
Price change (1Y)
-60.6%
Trailing year
Short interest
23.5%
Latest settlement · 9.0 days to cover
AI Brief
Q2 FY26 earnings call · Sep 22, 2026
Q2 FY26
TL;DR. Lexeo finalized the SUNRISE-FA 2 pivotal protocol for LX2006 in Friedreich ataxia cardiomyopathy and initiated the trial in June 2026, targeting topline data in 2H 2027 and a potential BLA in 1H 2028. LX2020 received FDA RMAT designation in PKP2-ACM. Cash of $234.2 million provides runway into 2028.
Bullish
- + Finalized SUNRISE-FA 2 pivotal trial protocol and SAP for LX2006 under the accelerated approval pathway, with study initiated in June 2026.
- + Phase I/II LVMI reductions exceed the 15% powering threshold and the 10% clinically meaningful benchmark for the pivotal study.
- + LX2020 received FDA RMAT designation in PKP2-ACM based on interim data, supporting potential expedited development.
- + LX2006 manufacturing is FDA-cleared for pivotal dosing with commercial-scale drug product immediately available.
- + Cash position of $234.2 million provides operational runway into 2028, through pivotal topline and potential BLA submission.
Bearish
- − Pivotal endpoints remain subject to ongoing FDA confirmatory evidence discussions, with no full-approval endpoint settled.
- − LX2020 reported one Grade 3 SAE of sustained ventricular tachycardia three months post-dosing (in addition to LFT elevations at high dose).
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
−25%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
−51%
trailing
YTD return
−67%
this year
Relative strength
−60%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
2 of 143 funds reported for Sep 30 · net +746 sh shares
Insider flow
Distributing
Net -$43.2K over 90 days · 100% sells
Short interest
Falling
23.46% of float · ▼ -6.7% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
143 holders — near 2-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
EPS growth
+40%
Y/Y
Free cash flow
$-99.0M
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
2 of 143 funds reported for Sep 30 · net +746 sh shares
Insider flow
Distributing
Net -$43.2K over 90 days · 100% sells
Short interest
Falling
23.46% of float · ▼ -6.7% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
143 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 1%
Range high $11
vs 200-day avg -43%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LXEO
this stock
Lexeo Therapeutics, Inc.
|
$265.01M | -67.5% | — | — | 23.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LXEO | -8.5% | -24.0% | -50.5% | -4.4% | -67.5% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -9.7% | -25.9% | -60.4% | -6.5% | -81.6% |